Chemotherapy

In popular usage, chemotherapy refers to a chemical treatment used to kill or halt the replication and/or spread of cancerous cells in a patient. The use of chemotherapy is not limited to cancer. Chemotherapeutic agents have also been used, with marginal success, against inflammatory diseases such as sarcoidosis and against pathogenic infections infections such as hepatitis C.

There is no official recommendation on whether patients and their physicians should use chemotherapeutic agents against cancer. However, there are two primary concerns about chemotherapy:

• Chemotherapy is immunosuppressive and drastically weakens the body's natural ability to fight infection.
• Chemotherapy targets fast-growing cells, but fails to target chronic pathogens and human cells infected by chronic pathogens.

Those patients who take a regimen of chemotherapy should explore with their physicians the option of using the Marshall ProtocolA curative medical treatment for chronic inflammatory disease. Based on the Marshall Pathogenesis. while on their chemotherapy.

The use of chemotherapeutic agents such as methotrexate (MTX) against sarcoidosis and other autoimmune diseases is not recommended.

There are variety of kinds of chemotherapy, but all chemotherapeutic regimens can cause depression of the immune system, often by paralyzing the bone marrow and leading to a decrease of white blood cells, red blood cells, and platelets. While some of the human cells which die are infected by intracellular pathogens, many are not. Chemotherapy's immunosuppressive effects are especially problematic when one considers that patients with cancer are already in a state of immunosuppression. In fact, according to the Marshall PathogenesisA description for how chronic inflammatory diseases originate and develop., patients develop cancer because they are immunosuppressed.

When the body is immunosuppressed, there are a number of important genes that are not properly expressed including those transcribed by the Vitamin D ReceptorA nuclear receptor located throughout the body that plays a key role in the innate immune response. (VDRThe Vitamin D Receptor. A nuclear receptor located throughout the body that plays a key role in the innate immune response.). One such gene is tumor metastasis suppressor protein,¹⁾ a protein which acts to slow or prevent metastases (secondary tumors) from spreading in the body of an organism with cancer.²⁾

The additional immunosuppression caused by chemotherapy can cause symptoms over the long-term such as “chemo brain.”³⁾

Methotrexate (MTX) is an antibiotic, which interferes with bacteria's ability to synthesize folate. It is used to treat diseases with rapid cell growth such as cancer and some autoimmune diseases. A superior alternative to MTX is the Marshall Protocol antibiotic, Bactrim DS:

MTX is an anti-folate – actually it is an anti-dihydrofolate reductase (anti-DHFR) – which inhibits one stage in the formation of DNA. Thus any bacteria dwelling within a body which has MTX in the bloodstream will find it more difficult to replicate, and hopefully the bacteria will gradually die off. Bactrim (Sulfa/trimeth) not only blocks DHFR (with trimethoprim) but also blocks P-ABA with Sulfonamide. Here is a diagram showing the Folate biochemistry in more detail. As you know, Bactrim is not a terribly effective antibiotic against intracellular pathogens, at least acting on its own. Neither is MTX especially effective acting on its own.

The interesting thing is that Folic Acid supplements are often given to ease the “side effects” of MTX. Folic Acid directly reduces the antibiotic action of both Trimethoprim and MTX. Sure, this may reduce pain from the immunopathologyA temporary increase in disease symptoms experienced by Marshall Protocol patients that results from the release of cytokines and endotoxins as disease-causing bacteria are killed., but wouldn't it be more sensible to just lower the dose of MTX and reduce the risk of liver damage.

Trevor Marshall, PhD

The antibiotic action of MTX is likely to increase the immunopathology associated with olmesartan (Benicar)Medication taken regularly by patients on the Marshall Protocol for its ability to activate the Vitamin D Receptor. therapy, which is why patients should discontinue MTX before starting the Marshall Protocol.

It is not harmful to the body to discontinue MTX abruptly. This is in contrast to Prednisone, where abruptly stopping can cause a number of serious problems. Some doctors think there is a risk of rebound inflammationThe complex biological response of vascular tissues to harmful stimuli such as pathogens or damaged cells. It is a protective attempt by the organism to remove the injurious stimuli as well as initiate the healing process for the tissue. from stopping methotrexate abruptly. Taking a few weeks to wean from MTX, while probably not necessary, is the cautious approach to avoid the symptoms of rebound inflammation.

In 2011, a Norwegian study published in PLoS One studied the effect of Rituximab – a monoclonal antibody otherwise used in cancers and anti-rejection treatment for organ transplants – on patients with chronic fatigue syndrome. In the 25-week study period, fatigue improved significantly in 10 out of 15 patients versus 2 out of 15 controls.⁴⁾ This positive result may be due to the fact that Rituximab is a strong immunosuppressant. It may be telling to see a follow up of the patients who received the drug ten or even fifteen years from now.

<html> <div class=“patientinterviews”>

<div class=“patientinterviewboxl”> <div class=“patientinterviewimage”></html><html></div> <div class=“patientinterviewtext”> <div class=“patientinterviewname”></html>Gene Johnson<html></div></html>

sarcoidosis, bladder cancer

Read the interview

<html></div></div></html>

<html>

<br clear=“left” />

</div> </html>

TECHEDIT

• Legacy content
  • http://www.marshallprotocol.com/view_topic.php?id=3094&forum_id=37&jump_to=45587#p45587 s43
  • http://www.marshallprotocol.com/view_topic.php?id=4285&forum_id=37&jump_to=91300#p91300 s132
  • http://www.marshallprotocol.com/view_topic.php?id=3094&forum_id=37&jump_to=28072#p28072 s31

If most of the morbidity in patients with diabetes is caused by high blood glucose levels, then control of those levels should return the system to normal and the patient's health problems should disappear. However, in one recent study this strategy of more intensive glucose control resulted in increased risk of death. Likewise, chemotherapy often initially reduces tumor size but also produces severe adverse effects leading to other complications, including the promotion of secondary tumors. Most important, little evidence exists that more aggressive chemotherapies prolong life for many patients.2-4 In fact, chemotherapies may have overall negative effects for some patients.

2. Mittra I. The disconnection between tumor response and survival. Nat Clin Pract Oncol. 2007;4(4):203. 3. SavageL.High-intensitychemotherapydoesnotimprovesurvivalinsmallcelllung cancer. J Natl Cancer Inst. 2008;100:519. 4. BearHD.Earlierchemotherapyforbreastcancer:perhapstoolatebutstilluseful. Ann Surg Oncol. 2003;10(4):334-335.

H.H. Weng⁵⁾

Some more interesting stuff here: http://jama.ama-assn.org/cgi/content/full/300/13/1580

In cancer research, system behavior has been monitored during cancer progression, demonstrating that cancer evolution is driven by multiple cycles of transition between genome system stability and instability.9-10 Chemotherapy, by and large, induces a relatively stable system to enter into a chaotic phase. This drastic treatment might be more harmful at the individual level than had been expected. Clearly, understanding the entire system response in the context of any specific treatment is key.

9. Weng HH, Stevens J, Liu G; et al. Stochastic cancer progression driven by non-clonal chromosome aberrations. J Cell Physiol. 2006;208(2):461-472. FULL TEXT | WEB OF SCIENCE | PUBMED | GET IT@WCMC

10. Ye CJ, Liu G, Bremer SW; et al. The dynamics of cancer chromosome and genome. Cytogenet Genome Res. 2007;118(2-4):237-246. FULL TEXT | WEB OF SCIENCE | PUBMED | GET IT@WCMC

Chemo: http://www.cancerdecisions.com/030506.html http://www.australianprescriber.com/magazine/29/1/2/3/